Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells
about
The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent CellsInvestigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemiaTherapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicInhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.Koschei the immortal and anti-aging drugsButein inhibits cell proliferation and induces cell cycle arrest in acute lymphoblastic leukemia via FOXO3a/p27kip1 pathwayCXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemiaAdipose-derived Mesenchymal Stem Cells (ASCs) may favour breast cancer recurrence via HGF/c-Met signaling.Heat shock protein 70 - the next chaperone to target in the treatment of human acute myelogenous leukemia?STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia.Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication.Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment.Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase.Downregulation of angiogenin inhibits the growth and induces apoptosis in human bladder cancer cells through regulating AKT/mTOR signaling pathway.In Vitro Characterization of Valproic Acid, ATRA, and Cytarabine Used for Disease-Stabilization in Human Acute Myeloid Leukemia: Antiproliferative Effects of Drugs on Endothelial and Osteoblastic Cells and Altered Release of Angioregulatory MediatorAntileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells.Targeting acute myeloid leukemia stem cell signaling by natural products.Potency and pharmacokinetics of broad spectrum and isoform-specific p110γ and δ inhibitors in cancers.Study on the function and mechanism of atorvastatin in regulating leukemic cell apoptosis by the PI3K/Akt pathway.SSeCKS/AKAP12 scaffolding functions suppress B16F10-induced peritoneal metastasis by attenuating CXCL9/10 secretion by resident fibroblasts.Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect.Predicting effects of kinase inhibitor in therapy for myeloid malignancies - the challenges in capturing disease heterogeneity.Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism.Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia.The Angiogenic Chemokines Expression Profile of Myeloid Cell Lines Co-Cultured with Bone Marrow-Derived Mesenchymal Stem Cells.Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies.Biological Aspects of mTOR in Leukemia
P2860
Q28074203-A3504896-3D16-4512-B0BD-3D824A34D6C0Q33943277-8051F3F3-AF8E-4018-B5CD-7DC027CE9CCAQ33952803-B30B6CB5-5430-4A40-83BA-6889D31AECDEQ34817365-7E1F0866-9E5E-4BE7-801D-4ACF2BCAF218Q35741623-7EF3B529-617A-4734-847A-FEC70A40C65FQ36292001-1873AA57-1721-41FF-A920-43F757BB9E69Q37109845-56B5D8E4-77E4-445C-859C-6E7CF5EF2135Q37299309-838AA79A-5D29-4426-A633-2BCAC2C49AC5Q37718453-C7E0D7D3-6A4A-474C-BAD0-55115D7AB63AQ38222563-44D7EFE5-32F9-46D2-BE32-E795A86A144FQ38265472-2A39EE4C-2B56-46B2-B02C-7706205DA0D0Q38401664-4662C7CD-4F0A-44F2-A042-927A41F74339Q38554422-93A1CFD3-EDC2-402F-AA93-DCADCE0FACDEQ38831784-8EB6033A-E1D9-4969-8D87-B51A1F3F86B0Q38893052-48087523-8CB3-4F70-B69B-9682681CF54DQ38922571-50E3B98D-0CC4-4135-B6C7-2E332CB96A5FQ39023971-3D4A8A26-746A-4E8F-97A3-BA5085233CE4Q39045977-11AF0C17-C496-4981-947A-7E079D4F8530Q39109921-67674CB4-0FF9-462F-A0A3-562214D9B179Q40082014-B39E21AE-1ED1-4EA2-82EE-605863030385Q41042432-C06BB7D3-C727-409E-8CB4-1B2BE10A3F01Q42378427-8951883B-1D6C-4281-9C8F-4B75E3954C71Q43461214-A2A8FBD6-BF8B-4B14-9689-A9662C267CFCQ44312541-2B8E62B9-D82D-44A4-8513-EBE3695181AAQ48043104-F9E404BB-BEDC-48CB-B25F-076A449A787BQ48592284-4E15264E-8CAE-4293-A47A-CB97C24A7385Q50116329-9953D9F2-F9BF-4A88-AA58-6C44FDAB8F25Q51818965-005536DD-0B57-4A0C-B7F9-F860DD29D94BQ58780065-DDF4C774-0031-4425-8EDA-7AAF00931CE4
P2860
Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacological targeting of t ...... heir neighboring stromal cells
@en
Pharmacological targeting of t ...... eir neighboring stromal cells.
@nl
type
label
Pharmacological targeting of t ...... heir neighboring stromal cells
@en
Pharmacological targeting of t ...... eir neighboring stromal cells.
@nl
prefLabel
Pharmacological targeting of t ...... heir neighboring stromal cells
@en
Pharmacological targeting of t ...... eir neighboring stromal cells.
@nl
P2093
P2860
P356
P1433
P1476
Pharmacological targeting of t ...... heir neighboring stromal cells
@en
P2093
Håkon Reikvam
Kimberley Joanne Hatfield
Øystein Bruserud
P2860
P304
P356
10.18632/ONCOTARGET.971
P407
P50
P577
2013-06-01T00:00:00Z